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S u m m a r y  
 
Renal anemia is one of the major complications observed 
in patients with chronic kidney disease (CKD). It is caused 
mainly by a relative erythropoietin deficiency due to 
progressive damage of renal parenchyma. The primary goal of 
anemia treatment using available today ESAs is not only to 
improve the quality of life of patients but, above all to reduce 
cardiovascular mortality. The target hemoglobin concentration 
during application of ESA in CKD patients treated 
conservatively and renal replacement therapy patients was and 
still is being discussed among nephrologists. Based on the 
clinical trials performed so far, it seems that in patients with 
renal anemia we should individualise treatment with ESA, 
seeking partial rather than complete correction of anemia.
 
 
S t r e s z c z e n i e  
 
Niedokrwistość nerkopochodna jest jednym z istotnych 
powikłań obserwowanych u pacjentów z przewlekłą chorobą 
nerek (PCHN). Jest ona spowodowana głównie względnym 
niedoborem erytropoetyny wskutek postępującego uszko-
dzenia miąższu nerek. Podstawowym celem leczenia 
niedokrwistości przy pomocy dostępnych współcześnie 
czynników stymulujących erytropoezę (ESA) jest nie tylko 
poprawa jakości życia chorych, ale przede wszystkim 
zmniejszenie śmiertelności sercowo-naczyniowej. Docelowe 
stężenie hemoglobiny w czasie stosowania ESA u pacjentów 
z PChN leczonych zachowawczo, jak i dializowanych, było  
i nadal jest przedmiotem dyskusji w środowisku nefrolo-
gicznym. W oparciu o  przeprowadzone do tej pory badania 
kliniczne wydaje się, iż w przypadku chorych z niedo-
krwistością nerkopochodną należy prowadzić indywidu-
alizację leczenia z zastosowaniem ESA, dążąc raczej do 
częściowej niż całkowitej korekcji niedokrwistości. 
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Anemia is one of the symptoms of chronic kidney 
disease (CKD) and an important cause of morbidity 
and cardiovascular mortality. ARIC Study 
(Atherosclerosis Risk In Communities) showed that the 
slight increase in serum creatinine levels (> 1.2 mg/dl 
in women, > 1.5 mg/dl in men) together with anemia 
occurrence was associated with almost 3-fold risk of 
coronary artery disease (CAD). A similar relationship 
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was not observed in patients with elevated creatinine 
level without accompanying anemia [1]. DOPPS study, 
which was published in 2004, showed that 1.0g/dl rise 
(from the baseline) in hemoglobin reduces mortality by 
5% [2]. 
In accordance with the criteria proposed by the 
WHO we recognize anemia when Hb is less than 13 
g/dl in men and postmenopausal women, and less than 
12 g/dl in women before menopause. According to the 
DOQI (Dialysis Outcome Quality Initiative), we deal 
with anemia when the Hb is about 1 g / dl lower than 
those defined by WHO [3]. 
 
THE PATHOGENESIS OF RENAL ANEMIA 
 
One of the important cause of anemia in CKD is 
reduced red blood cell production by the bone marrow, 
caused by deficiency of erythropoietin due to the 
progressive renal damage. The main site of 
erythropoietin production in adults are tubular 
epithelial cells and interstitial fibroblasts at the border 
of the cortex and outer core of the kidney. 
Erythropoietin synthesis is regulated in a feedback 
mechanism, depending on the oxygen partial pressure 
of blood flowing through the kidney. 
Red blood cell survival time in patients in advanced 
stages of chronic kidney disease is reduced to 1/3 
survival time of erythrocytes in healthy individuals. 
Shorten survival time of erythrocytes is a consequence 
of accumulation of uremic toxins and erythrocytes 
damage, as a result of mechanical and osmotic or 
oxidative stress as well as. 
Increased production of reactive oxygen species 
and impaired efficiency of antioxidant mechanisms in 
CKD lead to oxidative stress. This leads to increased 
plasma levels of lipid peroxidation products, protein, 
carbohydrates, and deoxyribonucleic acid [4]. It is 
believed that the impairment of the natural antioxidant 
system in erythrocytes is one of the most important 
factors increasing lipid peroxidation in erythrocyte 
membranes. This results in blood cell hemolysis, and 
therefore, intensification of anemia in patients with 
CKD [5]. CKD patients present significantly elevated 
plasma homocysteine level which is responsible for 
increased LDL oxididation in vascular wall. This 
results from the cytotoxic effects of homocysteine on 
the extracellular superoxide dismutase, whose activity 
decreases in direct proportion to the increase in 
concentration of homocysteine. In this way the vessel 
wall is deprived of the physiological antioxidant 
protection and becomes more susceptible to the 
harmful effects of reactive oxygen species [6]. 
Probably, intensification of lipid peroxidation in 
cellular membranes is one of the factors jointly 
responsible for the reduction of erythrocyte survival 
and development of renal anemia.  
On the other hand, it should be remembered that 
patients with CKD are exposed to repeated, frequent 
loss of blood due to gastrointestinal tract bleeding, 
frequent blood sampling for laboratory test and 
hemodialysis procedures itself (blood lose in 
extracorporeal circuit). It is estimated that during one 
hemodialysis session blood lose is approximately 20 
ml as a result of puncture of arteriovenous fistula and 
loss of blood in the dialyzer. It gives blood lose of 
approximately 3 000 ml per year. 
Moreover, drugs administration particularly 
commonly used ACE-I and AT1-blockers may 
aggravate renal anemia. It is related with deficiency of 
angiotensin II, which directly stimulates the synthesis 
of erythropoietin, reduce hypoxia, and is a strong 
stimulus for EPO production and may inhibit the 
proliferation of erythroblasts [7]. Thiazide diuretics 
administration may also (together with ARBs or ACE-I 
treatment) diminish endogenous production of 
erythropoietin by reducing oxygen supply as a result of 
active Na-Cl cotransporter inhibition in distal tubules 
[8]. 
Iron deficiency is the most common deficiency in 
CKD. Absolute iron deficiency in stage 4 - 5 CKD 
occurs when the transferrin saturation falls below 20% 
and ferritin levels is below 100 mg/ml [9]. In clinical 
practice, it is important to distinguish between 
functional iron deficiency, which corresponds to the 
treatment, and iron deficiency called ‘inflammation 
block’. The latter is accompanied by chronic diseases 
caused by inflammation, and there is no improvement 
due to iron supplementation in this case. 
The main objective of anemia treatment in patients 
with CKD is to improve quality of life and reduce 
mortality. It has been shown that the decrease in Hb of 
1 g/dl was associated with increased mortality in 14-
18% of the population of patients on dialysis, and the 
concentration of Hb below 8 g/dl resulted in two fold 
higher risk of death than the level of Hb 10-11 g/dl 
[10]. In many studies, both retrospective and 
prospective recommended range of concentrations of 
Hb was evaluated. Most of the researchers confirmed 
that the concentration of Hb> 11 g/dl affects better 
outcomes and and better improvement in quality of life 
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in both predialysis and renal replacement therapy 
patients. Hb concentration > 13 g/dl, paradoxically 
increases the morbidity and mortality. The target 
hemoglobin concentration should depend on clinical 
status, age, gender, physical activity, the coexistence of 
other factors of cardiovascular disease and dialysis 
modality. 
 
CONTROVERSY IN RENAL ANEMIA 
TREATMENT 
  
The CREATE STUDY and the CHOIR STUDY, 
the results of which were published in 2006, were the 
first trials to answer the question about hemoglobin 
concentration in chronic renal failure patients. Which 
therapeutic option is better – partial or complete 
correction of hemoglobin level?  
In the CREATE Study (Cardiovascular Risk 
Reduction by Early Anemia Treatment) 603 patients 
with chronic kidney disease (CKD) stage 3 and 4 
(eGFR range 15 to 35 ml/min per 1.73 m2 of body-
surface area) and mild-to-moderate anemia 
(hemoglobin level, 11.0 to 12.5 g per deciliter) were 
randomly assigned to a group with a target hemoglobin 
value in the normal range (13.0 to 15.0 g per deciliter, 
group 1) and to a group with subnormal range (10.5 to 
11.5 g per deciliter, group 2). Subcutaneous 
erythropoietin (epoetin beta) was initiated at 
randomization (group 1) or only after the hemoglobin 
level fell below 10.5 g per deciliter (group 2). During 
the 3 years observation, in spite of better quality of life 
in arm with higher hemoglobin concentration, there 
were no differences in left ventricular mass index 
between these two groups noted. Complete correction 
of anemia did not affect the likelihood of a first 
cardiovascular event (58 events in group 1 vs. 47 
events in group 2). The mean estimated GFR was 24.9 
ml per minute in group 1, and 24.2 ml per minute in 
group 2 at baseline, and decreased by 3.6 and 3.1 ml 
per minute per year, respectively (P=0.40). Dialysis 
was required in more patients in group 1 than in group 
2 (127 vs. 111, P=0.03). There were no differences in 
total mortality, cardiovascular mortality, 
hospitalizations rate between group 1 and group 2 [11]. 
The authors of the trial concluded that in patients with 
chronic renal failure, early complete correction of 
anemia does not reduce the risk of cardiovascular 
events.  
The CHOIR study (Correction of Hemoglobin and 
Outcomes in Renal Insufficiency) compromised 1432 
patients with CKD and Hb level below 11.0g per 
deciliter. Patients were randomly assigned to receive a 
dose of epoetin alfa targeted to achieve a hemoglobin 
level of 13.5 g per deciliter and other group to receive 
a dose targeted to achieve a level of 11.3 g per 
deciliter. Early termination of study was performed 
after 16 months because patients assigned to high 
hemoglobin group (target level 13,5g/dl) showed 
higher rate of cardiovascular events (CV death and 
hospitalization related to decompensated heart failure.) 
[12, 13].  
The results of these 2 studies proved that complete 
renal anemia correction is not beneficial for CKD 
patients and there is no reduction in cardiovascular 
mortality and the incidence of new cardiovascular 
events in this population. It is worth  noticing that 
higher morbidity and mortality rate in higher 
hemoglobin concentration arm was mainly related to 
toxicity of high dose of erytropoetin and intravenous 
iron administration but not by hemoglobin 
concentration >13.0g/dl itself. It appears that high dose 
of erythropoietin may activate RAAS, increase 
endothelin-1 (ET-1) production and diminish 
tromboxane and prostacycline release in vascular wall. 
This may lead to higher blood pressure and higher 
cardiovascular events rate [14]. Moreover, high 
erythropoietin dose in renal anemia treatment may 
contribute to tissue remodeling, intensification of 
chronic inflammation via activation of kB nuclei factor 
and increase production of many cytokines, growth 
factors and procoagulation mediators. This may lead to 
profibrogenic action of erythropoietin and other 
erytropoetin stimulation agents (ESA). [15].  
 High doses of ESA and fast correction of anemia 
may cause detrimental effects and may contribute to 
accelaration of CKD in patients on conservative 
treatment with Hb level above 13.0g/dl achieved in a 
very short time. On the other hand, in hemodialysis 
patients posthemodialysis hemoconcentration in 
individuals with Hb level>13.0g/dl may also cause 
higher cardiovacular events rate. Therefore, anemia 
treatment in this population should be very cautious.  
Another worth mentioning study is the TREAT trial 
(Trial to Reduce Cardiovascular Events with Aranesp 
Therapy) the results of which were published in 2009 
[16]. The TREAT was a randomized, double-blind, 
placebo-controlled trial conducted at 623 sites in 24 
countries. The TREAT trial tested the hypothesis that 
the use of ESA would improve outcomes in patients 
with diabetes and CKD. 4038 patients with diabetes 
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and CKD on conservative treatment were enrolled to 
the study. 2012 patients were randomized to 
darbopoetin alfa treatment to achieve Hb- 13.0g/dl and 
2026 to placebo arm. In placebo arm usage of 
darbopoetin alfa as a ‘rescue therapy’ was possible in 
patients with Hb level <9.0g/dl. The primary endpoints 
in this trial were: time to composite outcome of death 
from any cause or a CV event (MI, stroke, CHF, 
hospitalization for myocardial ischemia) and time to 
ESRD or death. Mean Hb concentration in 
darbepoetin-alfa arm was 12.5g/dl and in placebo arm 
it was 10.6g/dl. In this trial there were no statistically 
significant differences in death of any cause, 
occurrence of CV events (non fatal myocardial 
infarction (MI), unstable angina, heart failure, or 
stroke) and ESRD with dialysis requirements. In 
darbopoetin-alfa arm there was twofold increase in 
stroke risk and higher risk of death because of cancer 
in these patients in whom darbopoetin-alfa was started 
and there was cancer occurrence at the beginning of 
treatment with ESA. There was a reduction in the need 
for packed red blood cell transfusion with darbepoetin 
alfa, but a higher risk of venous and arterial 
thromboembolic events, as well as stroke, and a trend 
toward hypertension with the use of darbepoetin alfa. 
In placebo group, higher need for iron administration 
was observed. The authors of TREAT Trial concluded 
that there is no need for the routine use of ESAs in 
patients with diabetes and CKD on conservative 
treatment, and in each of patients commencement of 
ESA treatment requires awareness of benefits and risks 
of such decision. 
The range of Hb value during anemia treatment is 
still matter of debate. In the end of 2010 Food and 
Drug Administration suggested Hb range between 10-
12g/dl, NFK-DOQI recommendations from 2007 
suggested range between 11-12g/dl. It seems sensible 
not to exceed the value of 12.0g/dl during the 
correction or maintain phase of treatment. In spite of a 
great controversy in anemia treatment with usage of 
ESAs, such therapy is still valuable for CKD patients 
but should be individualized and safe in each case [17]. 
Iron deficiency plays an important role in 
pathogenesis of renal anemia, (it is the most common 
cause of hyporesponsiveness to ESAs) and iron status 
needs monitoring during ESAs administration. Iron 
plays crucial role not only in erythropoesis. Free iron 
activation may cause induction of inflammation, 
oxidative stress, and kidney damage especially when 
correction is made by intravenous iron administration. 
Iron absorption, transport and storage is regulated by 
specific protein such as transferin and ferritin. Annual 
iron loss in hemodialysis patients is approximately 
2.0g. Iron deficiency can be easily corrected by 
intravenous iron administration, which is more 
effective than oral iron supplementation because of 
inadequate iron absorption. Correction of iron 
deficiency may cause rise in hemoglobin level in most 
patients. There is strong suggestion that high dose of 
intravenous iron supplementation may accelerate 
cardiovascular damage and increased risk of bacterial 
infection. Several recent clinical studies have shown 
the opposite effects as long as intravenous iron was 
adequately dosed [18]. According to KDOQI 
guidelines, ferritin level in hemodialysis patients 
should be greater than 200mg/dl , but level greater than 
500mg/dl is an indication to iron supplementation 
withdrawal [3]. In the DRIVE study intravenous 
administration of ferric gluconate was highly 
efficacious in anemic hemodialysis patients with high 
serum ferritin level (>800mg/dl) and low transferrin 
saturation. 12 weeks of ferric gluconate 
supplementation in patients with ferritin level between 
500-1200mg/dl showed significant hemoglobin 
increase and diminish of ESAs dosage. But limitation 
of this study was: short time of observation and lack of 
information about the iron overdosing risk. [19]. In 
conclusion, we should always be aware of ESAs 
overdosing/toxicity, iron overdosing and toxicity 
during anemia treatment. Such awareness  facilitates 
the application of the best management strategy in both 
ESAs and iron dose titration in correction and 
maintenance therapy [20]. Commencement of ESAs 
treatment without iron status correction is appropriate. 
In American population based study, Ht range 
between 33-36% was related with lowest all caused, 
cardiovascular mortality and hospitalization rate due to 
infection in compare to Ht range between 30-33% [21]. 
In Normal Hematocrit Study – prospective study 
comparing outcomes in 1233 hemodialysis patients 
with congestive heart failure or ischemic heart disease 
receiving treatment with epoetin alfa who were 
randomly assigned to the normal-hematocrit group, and 
to the low-hematocrit group - attainment hematocrit 
level of 42% was related with 7% higher incidence of 
death in compare to low –hematocrit group. In high 
hematocrite group incidence of vascular-access 
thrombosis was significantly higher than in the low-
hematocrit group. There was no statistically significant 
differences in non fatal myocardial infarction, stroke or 
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hospitalization rate between two groups [22]. The 
authors of the study concluded that detrimental 
outcomes were associated with a normal hematocrit 
level and the target hematocrit value of 42% cannot be 
recommended in patients with cardiac disease who are 
undergoing hemodialysis. The results of this study 
were in accordance with further outcomes of the  
CHOIR study and the  CREATE study. 
Safety Hb value during ESAs treatment in CKD 
patients on conservative treatment and these on renal 
replacement therapy is still matter of debate. 
According to NFK-DOQI guidelines from 2007 it was 
ascertain that Hb level should be greater than 11.0g/dl 
but less than 13.0g/dl because  harm related with 
higher Hb level may be greater than benefits of such 
therapy in spite of quality of life improvement and 
avoidance of blood transfusion [13]. According to 
EBPG recommendations in individuals with diabetes 
or cardiovascular complications Hb level should be 
less than 12.0g/dl. Hb values above 14,0g/dl are not 
recommended. In each patient ESAs therapy should be 
individualized and concomitant diseases should be 
taken into consideration. In European guidelines, Hb 
value greater than 14.0g/dl is detrimental and such 
values may cause life threatening complications. As it 
was mentioned before the optimal Hb range is between 
10g/dl to 12.0g/dl. Deleterious effects of ESAs 
treatment may be rather related with EPO 




1. High cardiovascular events rate in renal anemia 
patients may be rather related with oxidative 
stress and inflammation than anemia itself.  
2. Complications of ESAs therapy and iron 
supplementation during renal anemia treatment 
may be related with ESAs/iron overload and 
toxicity.  
3. Safety Hb range during ESAs treatment is 
estimated between 10g/dl to 12g/dl. Hb>12.0g/dl 
may be dangerous for CKD patients and higher 
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